HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics

The redirectioning of drugs in the pharmaceutical market is a well-known practice to identify new therapies for parasitic diseases. The histone deacetylase inhibitors Tubastatin A (TST) and Suberoylanilide Hydroxamic Acid (SAHA), firstly developed for cancer treatment, are effective against protozoa...

Full description

Bibliographic Details
Main Authors: Carlla Assis Araujo-Silva, Wanderley De Souza, Erica S. Martins-Duarte, Rossiane C. Vommaro
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:International Journal for Parasitology: Drugs and Drug Resistance
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211320720300518
id doaj-daca4fcef25c47c8a10401a0db52502f
record_format Article
spelling doaj-daca4fcef25c47c8a10401a0db52502f2021-04-20T05:12:15ZengElsevierInternational Journal for Parasitology: Drugs and Drug Resistance2211-32072021-04-01152535HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeuticsCarlla Assis Araujo-Silva0Wanderley De Souza1Erica S. Martins-Duarte2Rossiane C. Vommaro3Laboratório de Ultraestrutura Celular Hertha Meyer - Universidade Federal do Rio de Janeiro - Instituto de Biofísica Carlos Chagas Filho, Av. Carlos Chagas Filho, 373 -Cidade Universitária, Rio de Janeiro - RJ, 21941-170, Brazil; Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, BrazilLaboratório de Ultraestrutura Celular Hertha Meyer - Universidade Federal do Rio de Janeiro - Instituto de Biofísica Carlos Chagas Filho, Av. Carlos Chagas Filho, 373 -Cidade Universitária, Rio de Janeiro - RJ, 21941-170, Brazil; Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, BrazilLaboratório de Quimioterapia de Protozoários Egler Chiari, Departamento de Parasitologia – ICB – Universidade Federal de Minas Gerais – Avenida Presidente Antônio Carlos, 6.627 –Pampulha - Belo Horizonte, MG, 31270-901, BrazilLaboratório de Ultraestrutura Celular Hertha Meyer - Universidade Federal do Rio de Janeiro - Instituto de Biofísica Carlos Chagas Filho, Av. Carlos Chagas Filho, 373 -Cidade Universitária, Rio de Janeiro - RJ, 21941-170, Brazil; Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, Brazil; Corresponding author. Laboratório de Ultraestrutura Celular Hertha Meyer - Universidade Federal do Rio de Janeiro - Instituto de Biofísica Carlos Chagas Filho, Av. Carlos Chagas Filho, 373 -Cidade Universitária, Rio de Janeiro - RJ, 21941-170, Brazil.The redirectioning of drugs in the pharmaceutical market is a well-known practice to identify new therapies for parasitic diseases. The histone deacetylase inhibitors Tubastatin A (TST) and Suberoylanilide Hydroxamic Acid (SAHA), firstly developed for cancer treatment, are effective against protozoa parasites. In this work, we aimed to demonstrate the activity of these drugs as potential agents against Toxoplasma gondii, the causative agent of toxoplasmosis. TST and SAHA were active against different genotypes of Toxoplasma gondii, such as, RH (type I), EGS (I/III) and ME49 (type II) strains. The IC₅₀ values for the RH strain were 19 ± 1 nM and 520 ± 386 nM for TST and 41 ± 3 nM and 67 ± 36 nM for SAHA, for 24 and 48 h, respectively. Both compounds were highly selective for T. gondii and their anti-proliferative effect was irreversible for 8 days. The calculated selectivity indexes (39 for TST and 30 for SAHA) make them lead compounds for the future development of anti-Toxoplasma molecules. Western blotting showed TST led to a significant increase of the nuclear histone H4 and a decrease of H3 acetylation levels. Treatment with 1 μM TST and 0.1 μM SAHA for 48 h decreased the amount of global α-tubulin. Fluorescence and electron microscopy showed that both drugs affected the endodyogeny process impairing the budding of daughter cells. The drugs led to the formation of large, rounded masses of damaged parasites with several centrosomes randomly dispersed and incorrect apicoplast division and positioning. TST-treated parasites showed a rupture of the mitochondrial membrane potential and led to a failure of the IMC assembling of new daughter cells. SAHA and TST possibly inhibit HDAC3 and other cytoplasmic or organelle targeted HDACs involved in the modification of proteins other than histones.http://www.sciencedirect.com/science/article/pii/S2211320720300518Toxoplasma gondiiHistone deacetylase inhibitorsApicomplexaAnti-parasitic chemotherapyEndodyogeny
collection DOAJ
language English
format Article
sources DOAJ
author Carlla Assis Araujo-Silva
Wanderley De Souza
Erica S. Martins-Duarte
Rossiane C. Vommaro
spellingShingle Carlla Assis Araujo-Silva
Wanderley De Souza
Erica S. Martins-Duarte
Rossiane C. Vommaro
HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
International Journal for Parasitology: Drugs and Drug Resistance
Toxoplasma gondii
Histone deacetylase inhibitors
Apicomplexa
Anti-parasitic chemotherapy
Endodyogeny
author_facet Carlla Assis Araujo-Silva
Wanderley De Souza
Erica S. Martins-Duarte
Rossiane C. Vommaro
author_sort Carlla Assis Araujo-Silva
title HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
title_short HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
title_full HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
title_fullStr HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
title_full_unstemmed HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
title_sort hdac inhibitors tubastatin a and saha affect parasite cell division and are potential anti-toxoplasma gondii chemotherapeutics
publisher Elsevier
series International Journal for Parasitology: Drugs and Drug Resistance
issn 2211-3207
publishDate 2021-04-01
description The redirectioning of drugs in the pharmaceutical market is a well-known practice to identify new therapies for parasitic diseases. The histone deacetylase inhibitors Tubastatin A (TST) and Suberoylanilide Hydroxamic Acid (SAHA), firstly developed for cancer treatment, are effective against protozoa parasites. In this work, we aimed to demonstrate the activity of these drugs as potential agents against Toxoplasma gondii, the causative agent of toxoplasmosis. TST and SAHA were active against different genotypes of Toxoplasma gondii, such as, RH (type I), EGS (I/III) and ME49 (type II) strains. The IC₅₀ values for the RH strain were 19 ± 1 nM and 520 ± 386 nM for TST and 41 ± 3 nM and 67 ± 36 nM for SAHA, for 24 and 48 h, respectively. Both compounds were highly selective for T. gondii and their anti-proliferative effect was irreversible for 8 days. The calculated selectivity indexes (39 for TST and 30 for SAHA) make them lead compounds for the future development of anti-Toxoplasma molecules. Western blotting showed TST led to a significant increase of the nuclear histone H4 and a decrease of H3 acetylation levels. Treatment with 1 μM TST and 0.1 μM SAHA for 48 h decreased the amount of global α-tubulin. Fluorescence and electron microscopy showed that both drugs affected the endodyogeny process impairing the budding of daughter cells. The drugs led to the formation of large, rounded masses of damaged parasites with several centrosomes randomly dispersed and incorrect apicoplast division and positioning. TST-treated parasites showed a rupture of the mitochondrial membrane potential and led to a failure of the IMC assembling of new daughter cells. SAHA and TST possibly inhibit HDAC3 and other cytoplasmic or organelle targeted HDACs involved in the modification of proteins other than histones.
topic Toxoplasma gondii
Histone deacetylase inhibitors
Apicomplexa
Anti-parasitic chemotherapy
Endodyogeny
url http://www.sciencedirect.com/science/article/pii/S2211320720300518
work_keys_str_mv AT carllaassisaraujosilva hdacinhibitorstubastatinaandsahaaffectparasitecelldivisionandarepotentialantitoxoplasmagondiichemotherapeutics
AT wanderleydesouza hdacinhibitorstubastatinaandsahaaffectparasitecelldivisionandarepotentialantitoxoplasmagondiichemotherapeutics
AT ericasmartinsduarte hdacinhibitorstubastatinaandsahaaffectparasitecelldivisionandarepotentialantitoxoplasmagondiichemotherapeutics
AT rossianecvommaro hdacinhibitorstubastatinaandsahaaffectparasitecelldivisionandarepotentialantitoxoplasmagondiichemotherapeutics
_version_ 1721518777127927808